CausesBy Mayo Clinic staff
There are two types of high blood pressure.
Primary (essential) hypertension
For most adults, there's no identifiable cause of high blood pressure. This type of high blood pressure, called essential hypertension or primary hypertension, tends to develop gradually over many years.
Some people have high blood pressure caused by an underlying condition. This type of high blood pressure, called secondary hypertension, tends to appear suddenly and cause higher blood pressure than does primary hypertension. Various conditions and medications can lead to secondary hypertension, including:
- Kidney problems
- Adrenal gland tumors
- Certain defects in blood vessels you're born with (congenital)
- Certain medications, such as birth control pills, cold remedies, decongestants, over-the-counter pain relievers and some prescription drugs
- Illegal drugs, such as cocaine and amphetamines
- Chobanian AV, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. New England Journal of Medicine. 2003;289:2560.
- Why blood pressure matters. American Heart Association. http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/WhyBloodPressureMatters/Why-Blood-Pressure-Matters_UCM_002051_Article.jsp. Accessed June 19, 2012.
- Aronow WS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Journal of the American College of Cardiology. 2011;57:2037.
- Kaplan NM, et al. Treatment of hypertension in blacks. http://www.uptodate.com/home/. Accessed June 19, 2012.
- Rosen CJ, et al. The nonskeletal effects of vitamin D: An Endocrine Society scientific statement. Endocrine Reviews. 2012;33:456.
- Kaplan NM, et al. Prehypertension. http://www.uptodate.com/home/. Accessed June 19, 2012.
- Calhoun DA, et al. Resistant hypertension: Diagnosis, evaluation and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;117:e510.
- Mann JFE. Choice of therapy in essential hypertension: Recommendations. http://www.uptodate.com/home/. Accessed June 19, 2012.
- Lopez L, et al. Lifestyle modification counseling for hypertensive patients: Results from the National Health and Nutrition Examination Survey 1999-2004. American Journal of Hypertension. 2009;22:325.
- Tseng C, et al. A predictive model for risk of prehypertension and hypertension and expected benefit after population-based life-style modification (KCIS No. 24). American Journal of Hypertension. 2012;25:171.
- Your guide to lowering blood pressure with DASH. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/. Accessed June 19, 2012.
- Appel LJ, et al. Dietary approaches to prevent and treat hypertension: A scientific statement from the American Heart Association. Hypertension. 2006;47:296.
- Pandic S, et al. Device-guided breathing exercises in the treatment of hypertension - perceptions and effects. CVD Prevention and Control. 2008;3:163.
- Natural medicines in the clinical management of hypertension. Natural Medicines Comprehensive Database. http://www.naturaldatabase.com. Accessed June 19, 2012.
- Home blood pressure monitoring. American Heart Association. http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/SymptomsDiagnosisMonitoringofHighBloodPressure/Home-Blood-Pressure-Monitoring_UCM_301874_Article.jsp. Accessed June 19, 2012.
- Dietary Guidelines for Americans, 2010. U.S. Department of Health and Human Services. http://www.cnpp.usda.gov/DGAs2010-PolicyDocument.htm. Accessed June 19, 2012.
- U.S. Preventive Services Task Force. Screening for high blood pressure: U.S. Preventive Services Task Force reaffirmation recommendation statement. Annals of Internal Medicine. 2007;147:783.
- Mayo Clinic statement: Aliskiren safety concern. Mayo Pharmaceutical Formulary Committee. http://mayoweb.mayo.edu/mfpfc-cmte/1112aliskirenStatement.pdf. Accessed June 19, 2012.
- Novartis announces termination of ALTITUDE study with Rasilez/Tekturna in high-risk patients with diabetes and renal impairment. Novartis International AG. http://www.novartis.com/downloads/newsroom/rasilez-tekturna-information-center/20111220-rasilez-tekturna.pdf. Accessed June 19, 2012.